Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 2,698 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Specimen #1 Clear all
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Not applicable Interventional

Advanced Diffusion Imaging in Renal Cancer Patients

NCT06116253
View directory record Official record
Conditions
Renal Cancer
Interventions
Magnetic Resonance Imaging (MRI) Scan, Tc-99m Pentetate
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting No phase listed Observational

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Phase 2 Interventional

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

NCT06390865
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sapanisertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Gainesville, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Blood on the PC Ratio During Pregnancy

NCT05434845
View directory record Official record
Conditions
Proteinuria in Pregnancy
Interventions
Blood draw
Other
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 18, 2026, 10:41 AM EDT
Completed No phase listed Observational

A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse

NCT07743281
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

NCT00702299
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, pemetrexed disodium, biologic sample preservation procedure
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Biology of Juvenile Myoclonic Epilepsy

NCT03400371
View directory record Official record
Conditions
Juvenile Myoclonic Epilepsy
Interventions
Blood draw, Existing samples
Other
Lead sponsor
King's College London
Other
Eligibility
10 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 18, 2026, 10:41 AM EDT
Withdrawn Phase 1 Interventional

Dexamethasone as an Immediate Intervention

NCT02753166
View directory record Official record
Conditions
Trauma
Interventions
Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

NCT03422731
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Neurocomputational Dynamics of Cooperation

NCT07759973
View directory record Official record
Conditions
Social Cognition, Personality Disorder, Mental Health, Interpersonal Conflict
Interventions
Social Learning Task Battery, Clinical Cohort, Social Learning Task Battery, Online Cohort
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
1,612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

NCT02003222
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
531
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 18, 2026, 10:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

NCT02896712
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM), Placebo, Modafinil
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Germ Cell Tumor and Testicular Tumor DNA Registry

NCT02099734
View directory record Official record
Conditions
Germ Cell Tumor, Testicular Tumor
Interventions
Questionnaires, sample of blood or saliva
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

NCT05518032
View directory record Official record
Conditions
Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 18, 2026, 10:41 AM EDT
Completed No phase listed Observational

Mechanisms of Ischemic Stroke in Cancer Patients

NCT02604667
View directory record Official record
Conditions
Stroke, Cancer
Interventions
Blood tests, Transcranial Doppler Microemboli Detection Study
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

NCT03921047
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT06609928
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Interventions
FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Pheresis, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

NCT05443971
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Durvalumab, Radiation Therapy, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Duloxetine Metabolism and Fibromyalgia

NCT06866444
View directory record Official record
Conditions
Fibromyalgia, Duloxetine
Interventions
Observational
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Stem Cells After Peripheral Mobilization and Harvest

NCT03381599
View directory record Official record
Conditions
Stem Cells, Orthopedic Disorder
Interventions
Filgrastim Injection
Drug
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
19 Years to 39 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 18, 2026, 10:41 AM EDT